Regulator Watch

Regulator Watch RegulatorWatch.com covers the issues, controversies and impacts arising from the regulation of economic, social and environmental activity in Canada/USA.
(1)

09/07/2026

Understanding the FDA's regulatory path can be complex. From 'Refuse to File' to scientific review and final decisions, learn about the stages, potential delays, and what deficiency letters mean for manufacturers.

09/07/2026

The number of va**ng products on the market has skyrocketed, yet teen va**ng rates have plummeted. This raises questions about public health strategies and whether focus should shift back to traditional smoking and enforcing illicit markets, where the real issues may lie. **ng

09/06/2026

Millions of PMTA applications submitted since 2021, yet FDA has rejected 99%. This creates a massive disconnect between product innovation and consumer access to potentially safer alternatives. **eIndustry ****neProducts

09/06/2026

Discover the stark differences between UK and US v**e regulations. While the UK embraces reduced harm with a 'light touch,' the US faces a complex legal landscape. Could innovation be stifled? **eRegulation ****ne

09/06/2026

Navigating the PMTA process involves distinct phases. Initially, an application review confirms correct forms are submitted. This is followed by a filing review, assessing if all required components, like stability or abuse liability studies, are present. Failure here results in a 'refuse to file' letter. If successful, the application proceeds to the scientific review, where FDA scientists evaluate all submitted data.

09/05/2026

Ni****ne pouches are not a fast-track system, but a faster one. The FDA recognizes their public health benefit for smokers. Unlike va**ng, pouches avoid heating and toxins, offering pharmaceutical-grade ni****ne in a simple cotton pouch. ****nePouches

09/05/2026

The FDA viewed teen va**ng as a crisis, swinging the pendulum towards strict regulation. Now, with that crisis subdued, the question arises: can the bar be lowered to allow innovative products for smokers? It's time to help those facing smoking-related diseases with better options. **ng

09/04/2026

The paradox of va**ng: devices effective at delivering ni****ne quickly for smoking cessation also carry high abuse liability. The FDA views ni****ne addiction as a public health consequence, akin to smoking-related diseases, despite ni****ne replacement therapies and long-term va**ng use not showing widespread death and disease. ****ne **ng

09/04/2026

The FDA is treating ni****ne use itself as the harm, even without smoke. This approach blocks safer alternatives like v**es while keeping ci******es on the market, despite growing evidence that ni****ne v**es help smokers quit. The agency continues to shift standards and create barriers for PMTA applicants. ****neRegulation **ng ***coScience

09/03/2026

The review process favors manufacturers with large market share, fast-tracking their products. This hinders small businesses and innovators with new technology. It stifles innovation and hands the ni****ne pouch industry to big to***co, which isn't good for the industry or consumers. ****nePouches ***co

Address

470 Granville Street , Suite 508
Vancouver, BC
V6C1V5

Website

,

Alerts

Be the first to know and let us send you an email when Regulator Watch posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category